Achieve Life Sciences Raises $124M, Details Plans for NDA


The company plans to submit its smoking cessation treatment to the FDA in the first half of 2025. It brought in money from Propel Bio Partners, Nantahala Capital, and Sopharma, among others. Per the direct offering and private placement, Achieve gets $60M upfront and $64.2M upon certain milestones.